Desensibilización a tipranavir por toxicodermia

Castro, B. Martínez; Piqueres, Raúl Ferrando; García, M. Martínez; Company, E. Soler

doi:10.1016/s1130-6343(09)72981-2

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Physicians commonly “treat through” mild ADRs to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine or efavirenz, hepatitis C drugs such as telaprevir and antibiotics such as beta-lactams and sulfa antimicrobials [160,161]. Desensitization protocols exist for hypersensitivity reactions to the antiretrovirals tipranavir [162], amprenavir [163], darunavir [164], efavirenz [165] and have been tried with nevirapine [166]. …”

Section: Summary and Recommendationsmentioning

confidence: 99%

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Konvinse

Phillips

White

et al. 2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Antimicrobials are a leading cause of severe T-cell-mediated adverse drug reactions (ADRs). The purpose of this review is to address the current understanding of antimicrobial cross-reactivity and the ready availability of and evidence for in vitro, in vivo and ex vivo diagnostics for T-cell-mediated ADRs. Recent findings Recent literature has evaluated the efficacy of traditional antibiotic allergy management including patch testing, skin prick testing, intradermal testing and oral challenge. While patch and intradermal testing are specific for the diagnosis of immune-mediated (IM) ADRs, they suffer from drug-specific limitations in sensitivity. The use of ex vivo diagnostics, especially ELISpot has been highlighted as a promising new approach to assigning causality. Knowledge of true rates of antimicrobial cross-reactivity aids empirical antibiotic choice in the setting of previous IM-ADRs. Summary In an era of increasing antimicrobial resistance and use of broad-spectrum antimicrobial therapy, ensuring patients are assigned the correct “allergy label” is essential. Re-exposure to implicated antimicrobials, especially in the setting of severe adverse cutaneous reaction is associated with significant morbidity and mortality. The process through which an antibiotic label gets assigned, acted on and maintained is still imprecise. Predicting T-cell-mediated ADRs via personalised approaches, including HLA-typing may pave future pathways to safer antimicrobial prescribing guidelines.

show abstract

Section: Summary and Recommendationsmentioning

confidence: 99%

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Konvinse

Phillips

White

et al. 2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Antiviral drugs

Lartey¹,

Torpey²,

Aronson³

2011

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Hypersensitivity reactions to HIV therapy

Chaponda

Pirmohamed

2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

Many drugs used for the treatment of HIV disease (including the associated opportunistic infections) can cause drug hypersensitivity reactions, which vary in severity, clinical manifestations and frequency. These reactions are not only seen with the older compounds, but also with the newer more recently introduced drugs. The pathogenesis is unclear in most cases, but there is increasing evidence to support that many of these are mediated through a combination of immunologic and genetic factors through the major histocompatibility complex (MHC). Genetic predisposition to the occurrence of these allergic reactions has been shown for some of the drugs, notably abacavir hypersensitivity which is strongly associated with the class I MHC allele, HLA-B*5701. Testing before the prescription of abacavir has been shown to be of clinical utility, has resulted in a change in the drug label, is now recommended in clinical guidelines and is practiced in most Western countries. For most other drugs, however, there are no good methods of prevention, and clinical monitoring with appropriate (usually supportive and symptomatic) treatment is required. There is a need to undertake further research in this area to increase our understanding of the mechanisms, which may lead to better preventive strategies through the development of predictive genetic biomarkers or through guiding the design of drugs less likely to cause these types of adverse drug reactions.

show abstract

Desensibilización a tipranavir por toxicodermia

Cited by 3 publications

References 4 publications

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Antiviral drugs

Hypersensitivity reactions to HIV therapy

Contact Info

Product

Resources

About